Time trend of prevalence and susceptibility to nitrofurantoin of urinary MDR Escherichia coli from outpatients
- 3 August 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (11) , 3264-3267
Abstract
Objectives: To assess the time trend of the prevalence of urinary MDR Escherichia coli in Belgian outpatients (2005 versus 2011–12), the antibiotic susceptibility of urinary MDR E. coli, and the time trend of non-susceptibility to nitrofurantoin, i.e. first-line treatment for uncomplicated urinary tract infections (UTIs), of urinary MDR E. coli (2005 versus 2011–12). Methods: In this secondary analysis of a multicentre study, which collected a convenience sample of voluntary participating laboratories (15 and 8 in 2005 and 2011–12, respectively), we analysed antimicrobial susceptibilities (ampicillin, amoxicillin/clavulanate, cefalotin, ciprofloxacin, nitrofurantoin and trimethoprim/sulfamethoxazole) of urinary E. coli. MDR was defined as resistance to three or more of these agents. The prevalence of MDR E. coli and its non-susceptibility to nitrofurantoin was compared between 2005 and 2011–12 using a generalized estimating equation model. Results: MDR status could be determined for 9704 and 12512 urinary E. coli isolates from 7911 and 9441 patients in 2005 and 2011–12, respectively, with most patients being women (79% in both study periods). The prevalence of MDR increased from 28.4% (2758/9704) in 2005 to 34.3% (4286/12512) in 2011–12 (adjusted OR 1.305; 95% CI 1.220–1.397). Within the MDR isolates, the prevalence of nitrofurantoin non-susceptibility decreased from 23.2% (623/2684) in 2005 to 10.7% (455/4253) in 2011–12 (adjusted OR 0.424; 95% CI 0.363–0.494). Conclusions: Despite a high prevalence of MDR E. coli in urinary samples from Belgian outpatients, nitrofurantoin could still be recommended as first-line empirical treatment in uncomplicated UTIs.Keywords
Funding Information
- Research Foundation – Flanders
- Fonds Wetenschappelijk Onderzoek
- University of Antwerp scientific chair
- Pfizer
- GlaxoSmithKline
- Methusalem financing programme of the Flemish Government
- Belgian National Council for the Promotion of Quality
- Nationale Raad voor Kwaliteitspromotie
This publication has 16 references indexed in Scilit:
- Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine CulturesAntimicrobial Agents and Chemotherapy, 2016
- Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012Antimicrobial Agents and Chemotherapy, 2016
- Epidemiology of urinary tract infections, bacterial species and resistances in primary care in FranceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Urinary tract infections: epidemiology, mechanisms of infection and treatment optionsNature Reviews Microbiology, 2015
- Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatientsJournal of Antimicrobial Chemotherapy, 2014
- Quality of antibiotic prescription during office hours and out-of-hours in Flemish primary care, using European quality indicatorsEuropean Journal of General Practice, 2013
- Urinary Tract Infections: Current and Emerging Management StrategiesClinical Infectious Diseases, 2013
- Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000-10Journal of Antimicrobial Chemotherapy, 2013
- Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University HospitalBMC Infectious Diseases, 2011
- Urinary Tract InfectionAnnals of Epidemiology, 2000